A Phase Ⅰb/Ⅱ Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R09b in Patients With Parkinson's Disease
Latest Information Update: 02 Jul 2024
At a glance
- Drugs VGN-R09 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Shanghai Vitalgen BioPharma
- 02 Jul 2024 New trial record